Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02120417
Title A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors Incyte Corporation
Indications

Her2-receptor negative breast cancer

Therapies

Capecitabine + Ruxolitinib

Capecitabine

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP


No variant requirements are available.